Recon: HHS OIG criticizes FDA’s EUA policies for COVID tests; ODAC votes against Spectrum’s lung cancer drug

ReconReconBiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy